Filing Details
- Accession Number:
- 0000899243-22-016135
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-05-02 17:34:26
- Reporting Period:
- 2022-04-28
- Accepted Time:
- 2022-05-02 17:34:26
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1235912 | Cvrx Inc. | CVRX | Surgical & Medical Instruments & Apparatus (3841) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1523522 | G. Kirk Nielsen | 9201 W Broadway Ave #650 Minneapolis MN 55445 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2022-04-28 | 100 | $5.97 | 1,570,198 | No | 4 | P | Indirect | See Footnote |
Common Stock | Acquisiton | 2022-05-02 | 41,988 | $5.97 | 1,612,186 | No | 4 | P | Indirect | See Footnote |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Indirect | See Footnote |
No | 4 | P | Indirect | See Footnote |
Footnotes
- These shares are held directly by Vensana Capital I, L.P. ("Vensana I"). The Reporting Person is a Managing Director of Vensana Capital I GP, LLC, the General Partner of Vensana I, and shares voting and dispositive power over the shares held by Vensana I. The Reporting Person disclaims beneficial ownership of all applicable shares except to the extent of his actual pecuniary interest in such shares.
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.85 to $6.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4.